🇺🇸 FDA
Patent

US 8501705

Methods and materials for treating autoimmune and/or complement mediated diseases and conditions

granted A61KA61K2039/505A61K31/713

Quick answer

US patent 8501705 (Methods and materials for treating autoimmune and/or complement mediated diseases and conditions) held by The Board of Regents of the University of Texas System expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K2039/505, A61K31/713, A61P, A61P29/00